News
12-10-2010, 03:31 AM
Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announces clinical results from ENCORE 401, a double-blind, placebo-controlled phase 2 trial, in patients with advanced non-small cell lung cancer (NSCLC). The results show that there was a survival advantage in the subset of patients with elevated E-cadherin (a molecular marker of epithelial tumors) receiving entinostat in combination with erlotinib (Tarceva®).
More... (http://www.news-medical.net/news/20101210/Entinostat-plus-erlotinib-improves-survival-in-NSCLC-patients-with-elevated-E-cadherin.aspx)
More... (http://www.news-medical.net/news/20101210/Entinostat-plus-erlotinib-improves-survival-in-NSCLC-patients-with-elevated-E-cadherin.aspx)